MedTrace Logo

VeraFlo With Prontosan® and Wound and Fracture Healing.

NCT02621073 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-06-20

Study results available
· View outcomes & findings →

Summary

To answer the question: "Do Prontosan instillations decrease time to wound and fracture healing and decrease bacterial load compared to wound vac treatment without Prontosan?," we will enroll up to 30 subjects (for an anticipated 20 complete data sets) into this trial. The subjects will be split equally into two different groups by randomization. One groups will have wound vac therapy with Prontosan, and one group will have wound vac therapy without Prontosan. Data related to wound and fracture healing and bacterial load will be assessed between the two groups to determine if wound vac therapy with Prontosan speeds up healing time and decreases bacterial load.

Conditions

Interventions

DRUG

VeraFlo with Prontosan

VeraFlo device with Prontosan instillation (n=10).

DEVICE

V.A.C Ulta System

V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).

Sponsors & Collaborators

  • Brett Crist

    lead OTHER

Principal Investigators

  • Brett D Crist, MD · University of Missouri, Missouri Orthopaedic Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02621073 on ClinicalTrials.gov